Advances in Discovery, Formulation, and Delivery of New Modalities
Ankit Kanthe, PhD
Senior Scientist
Bristol Myers Squibb
New Brunswick, New Jersey
The immuno-oncology landscape has witnessed remarkable progress in recent years, with the advent of immune checkpoint inhibitors revolutionizing the treatment paradigm for various malignancies. A brief overview on the latest advancements in immuno-oncology, including the development of novel checkpoint inhibitors, combination therapies, and biomarkers for patient stratification will be discussed. Monoclonal antibodies (mAbs) represent a cornerstone of cancer therapy, offering targeted approaches with reduced systemic toxicity. However, the interactions between mAbs and excipients present in formulations can significantly impact their stability, efficacy, and safety. Novel techniques and analytical approaches employed to study mAb-excipient interactions will be presented. Additionally, the recent hot topic around Antibody-drug conjugates (ADCs) and its formulation challenges for lyophilized drug product will also be discussed. Finally, an overview on the novel modalities for cancer treatment and drug delivery, such as chimeric antigen receptor T-cell therapy (CAR-T) and gene therapy, and the challenged associated with these modalities will be addressed. By elucidating these topics, this abstract aims to facilitate a deeper understanding of the current state-of-the-art in cancer therapy and inspire future research directions aimed at improving patient outcomes in oncology.